Stroke prevention in elderly patients with atrial fibrillation

Lancet

Volumn 370, Issue 9586, 2007, Pages 460-461

  Garcia, David ^a   Hylek, Elaine ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DIABETES MELLITUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; STROKE;

EID: 34547680113     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61208-2     Document Type: Note

References (9)

1. Hart R., Pearce L., and Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007) 857-867
2. Mant J., Hobbs F., Fletcher K., and on behalf of the BAFTA investigators and the Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370 (2007) 493-503
3. Fuster V., Ryden L., Cannom D., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary. Circulation 114 (2006) 700-752
4. Gage B., Waterman A., Shannon W., Boechler M., Rich M., and Radford M. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001) 2864-2870
5. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
6. Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293 (2005) 690-698
7. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
8. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of Vascular Events (ACTIVE W). Lancet 367 (2006) 1903-1912
9. Hylek E., Evans-Molina C., Shea C., Henault L., and Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007) 2689-2696